Glenmark Pharmaceuticals slumps after USFDA issues CRL for Ryaltris 0 24.06.2019 06:59 Business Standard Glenmark Pharmaceuticals fell 6.05% to Rs 469.95 at 10:09 IST on the BSE after the company said that US drug regulator issued complete response letter For Ryaltris. Moscow.media Частные объявления сегодня Rss.plus Все новости за 24 часа
